This analysis examines the historical and forecast performance for Recordati in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Recordati’s performance against key rivals in the ethical pharmaceutical sector
See how the company will give new life to its internally developed and strategically important Lercadip franchise through the launch of Zanipress
Assess the prospects of Recordati’s largely in-licensed but well-populated product portfolio
